Padagis Us Patent-Cliff Exposure & CMS Drug Spending Portfolio
Padagis Us (US): 3 reconciled FDA prescription therapies (6.4% 2025 to 2030 cliff risk), $15.0M 2024 CMS Part D & Medicaid spend.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Headquarters / Cluster | US |
| Reconciled FDA Portfolio Therapies | 3 |
| 2025 to 2030 Patent-Cliff Revenue Exposure | 6.4% |
| Primary Portfolio LOE Date | 2026-01-01 |
| 2024 CMS Total Public Spend | $15.0M |
| 2024 Medicare Part D Spend | $10.2M |
| 2024 Medicaid Spend | $4.8M |
| California HCAI SB 17 Filings | 0 statutory filings in 2023 to 2026 panel |